Sage Journals: Discover world-class research

Open access

Research article

First published 2021

A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults

Robert Croop, Andrea Ivans, Matt S Anderson [...]

Cephalalgia Reports

Retricted access

Review article

First published 2021-5

Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review

Alicia Potter DeFalco, Rachel Lazim, Nathan E. Cope

Annals of Pharmacotherapy

Retricted access

Research article

First published 2025-2

Identification and characterization of unknown oxidation degradation products of Rimegepant by HPLC and triple quadrupole mass spectrometry

Narayana Reddy Godi, Sireesha Dodda, Nagavardhana Reddy Vanga [...]

European Journal of Mass Spectrometry

Open access

Research article

First published 2023-2

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

Richard B Lipton, Andrew Blumenfeld, Christopher M Jensen [...]

Cephalalgia

Open access

Research article

First published 2025-7

A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data

Stewart J. Tepper, Aaron Jenkins, Carl Henriksen [...]

Cephalalgia

Open access

Research article

First published 2025-10

Rimegepant for the acute treatment of migraine: A phase 3,multicenter,open-label,long-term safety and effectiveness study in adults from China

Mingjie Zhang, Aihong Guo, Jin Wu [...]

Cephalalgia

Open access

Research article

First published 2025

Comparative efficacy,safety,and number needed to treat analysis of atogepant and rimegepant for the preventive treatment of episodic migraine in Japanese participants: An indirect comparison analysis

Takao Takeshima, Yasuhiko Matsumori, Gina Ahmadyar [...]

Cephalalgia Reports

Open access

Research article

First published 2025-7

Rimegepant safety and patient-reported outcomes among triptan-naïve,triptan-using,and triptan-failure participants: Subgroup analysis of an open-label,multicenter study

Jessica Ailani, Jelena Pavlovic, Glenn C Pixton [...]

Cephalalgia

Open access

Research article

First published 2022

Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term,open-label study

Gilbert L’Italien, Evan Popoff, Karissa Johnston [...]

Cephalalgia Reports

Open access

Research article

First published 2026

Use of mediation modeling to examine the relationships among treatment with rimegepant,headache pain severity,and functional disability in patients with migraine

Lucy Abraham, Andrew G. Bushmakin, Dawn C. Buse [...]

Cephalalgia Reports

Search results